MedTrace Logo

Treatment of High Altitude Polycythemia by Acetazolamide

NCT00424970 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2013-01-24

No results posted yet for this study

Summary

The prevalence of High Altitude Polycythemia (or Chronic Mountain Sickness) is between 8 and 15% in the high altitude regions of South America. There is no pharmacological treatment available. After a first preliminary study in 2003 demonstrating the beneficial effects of acetazolamide in reducing hematocrit in these patients, after 3 weeks of treatment, we want to confirm this effect and implement a treatment protocol of 3 month-duration.

Conditions

  • High Altitude Polycythemia

Interventions

DRUG

acetazolamide

Sponsors & Collaborators

  • University of Paris 13

    collaborator OTHER

  • Universidad Peruana Cayetano Heredia

    collaborator OTHER

  • Legs Poix

    collaborator UNKNOWN

  • Association pour la Recherche en Physiologie de l'Environnement

    lead OTHER

Principal Investigators

  • Jean-Paul Richalet, MD, PHD · ARPE, University Paris 13

  • Fabiola Leon-Velarde, PHD · University Cayetano Heredia, Lima, Peru

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Completion
2007-11-30

Countries

  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00424970 on ClinicalTrials.gov